DE60324544D1 - Muskarin antagonisten - Google Patents

Muskarin antagonisten

Info

Publication number: DE60324544D1
Authority: DE; Germany
Prior art keywords: sup; formula; compound; muscarin; antagonists
Prior art date: 2002-04-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60324544T

Other languages

English (en)

Inventor

Craig D Boyle

William J Greenlee

Samuel Chackalamannil

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme LLC

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-26

Filing date

2003-04-24

Publication date

2008-12-18

2003-04-24 Application filed by Schering Corp filed Critical Schering Corp

2008-12-18 Application granted granted Critical

2008-12-18 Publication of DE60324544D1 publication Critical patent/DE60324544D1/de

2023-04-25 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

DE60324544T 2002-04-26 2003-04-24 Muskarin antagonisten Expired - Lifetime DE60324544D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37609302P	2002-04-26	2002-04-26
PCT/US2003/012694 WO2003091220A1 (en)	2002-04-26	2003-04-24	Muscarinic antagonists

Publications (1)

Publication Number	Publication Date
DE60324544D1 true DE60324544D1 (de)	2008-12-18

Family

ID=29270760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60324544T Expired - Lifetime DE60324544D1 (de)	2002-04-26	2003-04-24	Muskarin antagonisten

Country Status (11)

Country	Link
US (1)	US6890936B2 (de)
EP (1)	EP1499596B1 (de)
JP (2)	JP4527408B2 (de)
CN (1)	CN1649845A (de)
AT (1)	ATE413388T1 (de)
AU (1)	AU2003228674A1 (de)
CA (1)	CA2484217A1 (de)
DE (1)	DE60324544D1 (de)
ES (1)	ES2315494T3 (de)
MX (1)	MXPA04010552A (de)
WO (1)	WO2003091220A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101120414B1 (ko)	2003-04-24	2012-04-12	인사이트 코포레이션	메탈로프로테아제의 억제제로서의 아자 스피로 알칸 유도체
WO2006034089A1 (en) *	2004-09-20	2006-03-30	Targacept, Inc.	Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity
JP2009506069A (ja) *	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
AU2007299920A1 (en) *	2006-09-19	2008-03-27	Braincells, Inc.	PPAR Mediated Modulation of Neurogenesis
WO2008036846A2 (en) *	2006-09-22	2008-03-27	Braincells, Inc.	Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US20080108574A1 (en) *	2006-09-27	2008-05-08	Braincells, Inc.	Melanocortin receptor mediated modulation of neurogenesis
JP5379692B2 (ja)	2006-11-09	2013-12-25	プロビオドルグエージー	潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (de)	2006-11-30	2012-04-18	Probiodrug AG	Neue inhibitoren von glutaminylcyclase
AU2008220785B2 (en)	2007-03-01	2013-02-21	Vivoryon Therapeutics N.V.	New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en)	2007-04-18	2008-10-30	Probiodrug Ag	Thiourea derivatives as glutaminyl cyclase inhibitors
TW200902007A (en) *	2007-05-25	2009-01-16	Astrazeneca Ab	Spirocyclopropyl piperidine derivatives
US20100130477A1 (en) *	2008-11-25	2010-05-27	Astrazeneca Ab	Spirocyclobutyl Piperidine Derivatives
WO2011029920A1 (en)	2009-09-11	2011-03-17	Probiodrug Ag	Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CA2789014C (en)	2010-02-09	2019-01-15	Michela Gallagher	Methods and compositions for improving cognitive function
EP2542549B1 (de)	2010-03-03	2016-05-11	Probiodrug AG	Glutaminylcyclase-hemmer
AU2011226074B2 (en)	2010-03-10	2015-01-22	Vivoryon Therapeutics N.V.	Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en)	2010-04-21	2013-09-24	Probiodrug Ag	Inhibitors
US20110281853A1 (en)	2010-05-12	2011-11-17	Rishi Arora	Compositions and methods for treating or preventing atrial fibrillation
US8530670B2 (en)	2011-03-16	2013-09-10	Probiodrug Ag	Inhibitors
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物
US11160785B2 (en)	2013-03-15	2021-11-02	Agenebio Inc.	Methods and compositions for improving cognitive function
EP3827820A1 (de)	2013-03-15	2021-06-02	The Johns Hopkins University	Brivaracetam zur verbesserung der kognitiven funktion
MA40858A (fr)	2014-10-31	2021-03-31	Indivior Uk Ltd	Composés antagonistes des récepteurs d3 à la dopamine
HK1251980B (en)	2015-05-22	2020-07-10	Agenebio, Inc.	Extended release pharmaceutical compositions of levetiracetam
US20220048913A1 (en) *	2017-07-12	2022-02-17	Vanderbilt University	Antagonists of the muscarinic acetylcholine receptor m4
DK3461819T3 (da)	2017-09-29	2020-08-10	Probiodrug Ag	Inhibitorer af glutaminylcyklase
US11325896B2 (en)	2017-12-20	2022-05-10	Vanderbilt University	Antagonists of the muscarinic acetylcholine receptor M4
TWI767148B (zh) *	2018-10-10	2022-06-11	美商弗瑪治療公司	抑制脂肪酸合成酶(fasn)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04225953A (ja) *	1990-05-07	1992-08-14	Shionogi & Co Ltd	スピロ　ジベンゾスベラン誘導体
GB9309422D0 (en) *	1993-05-07	1993-06-23	Res Inst Medicine Chem	Chemical compounds
AU2206699A (en) *	1997-12-23	1999-07-12	Alcon Laboratories, Inc.	Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
EP1386920A4 (de) *	2001-04-20	2005-09-14	Banyu Pharma Co Ltd	Benzimidazolonderivate

2003
- 2003-04-24 JP JP2003587783A patent/JP4527408B2/ja not_active Expired - Fee Related
- 2003-04-24 WO PCT/US2003/012694 patent/WO2003091220A1/en not_active Ceased
- 2003-04-24 AU AU2003228674A patent/AU2003228674A1/en not_active Abandoned
- 2003-04-24 AT AT03726436T patent/ATE413388T1/de not_active IP Right Cessation
- 2003-04-24 CN CNA038094436A patent/CN1649845A/zh active Pending
- 2003-04-24 DE DE60324544T patent/DE60324544D1/de not_active Expired - Lifetime
- 2003-04-24 EP EP03726436A patent/EP1499596B1/de not_active Expired - Lifetime
- 2003-04-24 CA CA002484217A patent/CA2484217A1/en not_active Abandoned
- 2003-04-24 MX MXPA04010552A patent/MXPA04010552A/es unknown
- 2003-04-24 ES ES03726436T patent/ES2315494T3/es not_active Expired - Lifetime
- 2003-04-28 US US10/425,376 patent/US6890936B2/en not_active Expired - Fee Related
2009
- 2009-12-16 JP JP2009285736A patent/JP2010059213A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CA2484217A1 (en)	2003-11-06
US6890936B2 (en)	2005-05-10
EP1499596A1 (de)	2005-01-26
MXPA04010552A (es)	2005-01-25
HK1068136A1 (en)	2005-04-22
JP2006507220A (ja)	2006-03-02
JP2010059213A (ja)	2010-03-18
EP1499596B1 (de)	2008-11-05
WO2003091220A1 (en)	2003-11-06
US20040067972A1 (en)	2004-04-08
AU2003228674A1 (en)	2003-11-10
ES2315494T3 (es)	2009-04-01
JP4527408B2 (ja)	2010-08-18
ATE413388T1 (de)	2008-11-15
CN1649845A (zh)	2005-08-03

Publication	Publication Date	Title
DE60324544D1 (de)	2008-12-18	Muskarin antagonisten
ATE425149T1 (de)	2009-03-15	ANILINOPYRIMIDIN DERIVATE ALS ßJNK PATHWAY INHIBITORENß, ZUSAMMENSETZUNGEN UND DAMIT VERBUNDENE BEHANDLUNGSMETHODEN
IS6658A (is)	2002-12-17	Ný efnasambönd
DE69725825D1 (de)	2003-12-04	5-HT1F-Agonisten
BRPI0410630A (pt)	2006-06-13	antagonista de nk1
IL166271A0 (en)	2006-01-15	Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
SE0101675D0 (sv)	2001-05-11	Novel composition
ATE433447T1 (de)	2009-06-15	Pyrimiidinverbindungen
PT1263725E (pt)	2005-02-28	Novos compostos
DE60142921D1 (de)	2010-10-07	Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
ATE371656T1 (de)	2007-09-15	Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE60140695D1 (de)	2010-01-14	Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren
ATE296826T1 (de)	2005-06-15	Pyrazolo(1,5)pyridinderivate
UA88012C2 (uk)	2009-09-10	Похідні хіназоліндіону як інгібітори parp
BR0307833A (pt)	2004-12-07	Sìntese controlada de ziprasidona e suas composições
ATE374190T1 (de)	2007-10-15	Tetrahydrochinazolinderivate als cfr-antagonisten
PL376324A1 (en)	2005-12-27	Piperazinyl and diazapanyl benzamides and benzthioamides
ATE410203T1 (de)	2008-10-15	Lipase-hemmende zusammensetzung
ATE369348T1 (de)	2007-08-15	Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
BR0212899A (pt)	2004-11-03	Compostos orgânicos
BG105710A (en)	2002-02-28	5ht1 antagonists for antidepressant therapy
NO20002408D0 (no)	2000-05-09	5-HT1F antagonister
MXPA03008801A (es)	2004-02-18	Aril oxima-piperazinas utiles como antagonistas de ccr5.
ATE335739T1 (de)	2006-09-15	Cak inhibitoren und deren verwendungen
ATE393624T1 (de)	2008-05-15	Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs

Legal Events

Date	Code	Title	Description
2009-11-26	8364	No opposition during term of opposition